Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lee, R. T.
Right arrow Articles by Papadopoulos, K. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, R. T.
Right arrow Articles by Papadopoulos, K. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:1245-1247, 1999
© 1999 European Society for Medical Oncology

other

Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel

R. T. Lee1,, M. W. Oster1, C. Balmaceda2, C. S. Hesdorffer1, L. T. Vahdat1 and K. P. Papadopoulos1

1Departments of Medicine, Divisions of Medical Oncology and Hematology New York, NY, USA
2Departments of Neurology, Columbia University College of Physicians and Surgeons New York, NY, USA

Correspondence to: R.T. Lee, MD, Division of Medical Oncology, College of Physicians and Surgeons of Columbia University, 177 Fort Washington Avenue, Room MHB 6-435, New York, NY 10032, USA.

Bilateral facial nerve palsy is an uncommon occurrence. We describe a case of bilateral facial nerve palsy secondary to a single cycle of high-dose paclitaxel therapy (825 mg/m2), in a woman with breast cancer. Prior to her high-dose therapy, she had a residual grade 2 peripheral neuropathy following treatment with ten cycles of standard-dose paclitaxel (total dose 3200 mg). The features of the peripheral neuropathy due to standard-dose paclitaxel, which can be both motor and sensory, are well described. Cumulative paclitaxel dose is considered a risk factor for development of the neuropathy. Although facial nerve palsy secondary to paclitaxel is not previously reported, other cranial nerve toxicity has been described. Consistent with reports of the reversibility of paclitaxel-induced peripheral neuropathy, the facial nerve palsies in our patient resolved over 23 months. Ongoing studies of high-dose paclitaxel warrant close attention to its cumulative neurotoxic effects, particularly in patients previously treated with neurotoxic chemotherapy.

bilateral facial nerve palsy, neurotoxicity, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
B. Damascelli, G. L. Patelli, R. Lanocita, G. D. Tolla, L. F. Frigerio, A. Marchiano, F. Garbagnati, C. Spreafico, V. Ticha, C. R. Gladin, et al.
A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings
Am. J. Roentgenol., July 1, 2003; 181(1): 253 - 260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Vahdat, K. Papadopoulos, D. Lange, S. Leuin, E. Kaufman, D. Donovan, D. Frederick, E. Bagiella, A. Tiersten, G. Nichols, et al.
Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine
Clin. Cancer Res., May 1, 2001; 7(5): 1192 - 1197.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.